{
  "pmcid": "12505526",
  "sha256": "d1f1dcd5167e01f1b2c3775c1c675edbc4786a8afeee750fa5968a8ed0bac503",
  "timestamp_utc": "2025-11-09T15:45:54.687687+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 11.898280632411069,
    "reading_ease": 27.08949452721194,
    "word_count": 253
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Residual neuromuscular blockade (RNB) is linked to an increased risk of perioperative adverse events."
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Participants": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Intervention": {
        "score": 2,
        "evidence": "The meta-analysis revealed that sugammadex facilitated faster reversal of RNB compared to neostigmine."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study systematically evaluates the impact of neuromuscular blockade antagonists on postoperative complications and quality of recovery in surgical patients."
      },
      "Method_Outcome": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The meta-analysis revealed that sugammadex facilitated faster reversal of RNB compared to neostigmine, as indicated by a quicker recovery to a Train-of-Four ratio (TOFR) ≥ 0.9 (standardized mean difference [SMD] −3.45; 95% confidence interval [CI], −4.42 to −2.48), a shorter extubation time (SMD −1.44; 95% CI, −2.02 to −0.85), and a decreased incidence of RNB (risk ratio [RR] 0.18; 95% CI, 0.07 to 0.47)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Moreover, sugammadex significantly reduced postoperative complications compared to neostigmine, including the incidence of postoperative nausea and vomiting (PONV) (RR 0.64; 95% CI, 0.46 to 0.88), postoperative pulmonary complications (PPCs) (RR 0.62; 95% CI, 0.38 to 0.99), and bradycardia (RR 0.32; 95% CI, 0.20 to 0.50)."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 7,
    "max_score": 25
  }
}